Pharmacological Pain Management in Patients with Post-Treatment Lyme Disease Syndrome
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Zhaodi Gong und 2 weiteren Autor:innen.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Lyme disease is an increasingly prevalent tick-borne illness associated with diverse pain manifestations, including arthralgia, myalgia, neuropathy, headache, etc. Persistent pain in patients with post-treatment Lyme disease syndrome can substantially impair quality of life and functional capacity, presenting challenges for clinicians due to its multifactorial etiology and variable response to treatment. A comprehensive review is divided into three series with specific focus on pharmacological therapies, interventional procedures, and complementary approaches to manage pain associated with post-treatment Lyme disease syndrome within a biopsychosocial framework.
Objective
To review pharmacological strategies for managing pain associated with post-treatment Lyme disease syndrome, emphasizing non-opioid medications as the first line and opioids as the last resort.
Methods
This review is one of the three series paper examining the clinical presentations and management of nociceptive and neuropathic pain associated with post-treatment Lyme disease syndrome, highlighting conventional and emerging therapeutic approaches.
Discussion
Effective pain management in patients with post-treatment Lyme disease syndrome requires identifying the underlying pain mechanisms, evaluating alternative diagnoses, and excluding active or recurrent infection when clinically indicated. Pharmacological treatments include topical analgesics, nonsteroidal anti-inflammatory drugs, and neuropathic agents. Emerging non-opioid therapies, including selective sodium-channel inhibitors, may offer additional options for acute pain. Adjuvants especially muscle relaxants may help ease the discomfort from pain but should be used with caution due to dependency potential and sedation side effects. Opioids may be considered selectively for refractory pain following individualized risk-benefit assessment and appropriate monitoring.
Conclusions
Pain associated with post-treatment Lyme disease syndrome warrants an individualized, multidisciplinary approach integrating pharmacological, interventional, physical, and psychological therapies. Prioritizing non-opioid strategies, identifying specific pain generators, and incorporating appropriate adjunctive treatments may improve symptomatic control and functional outcomes. Further controlled studies are needed to establish the efficacy, safety, and long-term benefits of emerging therapies in this population.
Zitieren
APA
Gong, Z., Gao, J., & Ren, T. (2026). Pharmacological Pain Management in Patients with Post-Treatment Lyme Disease Syndrome. Medical Research Archives. https://doi.org/10.18103/mra.2026.0781
Vancouver
Gong Z, Gao J, Ren T. Pharmacological Pain Management in Patients with Post-Treatment Lyme Disease Syndrome. Medical Research Archives. 2026. doi:10.18103/mra.2026.0781
BibTeX
@article{Gong2026,
author = {Gong, Zhaodi and Gao, Jiachen and Ren, Tianjiao},
title = {Pharmacological Pain Management in Patients with Post-Treatment Lyme Disease Syndrome},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0781}
}
EUVIMED